vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and WORKIVA INC (WK). Click either name above to swap in a different company.
WORKIVA INC is the larger business by last-quarter revenue ($238.9M vs $196.0M, roughly 1.2× Axsome Therapeutics, Inc.). WORKIVA INC runs the higher net margin — 4.9% vs -14.6%, a 19.5% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 19.5%). WORKIVA INC produced more free cash flow last quarter ($50.7M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 16.6%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Workiva, Inc. is a global software-as-a-service (SaaS) company. It provides a cloud-based connected and reporting compliance platform that enables the use of connected data and automation of reporting across finance, accounting, risk, and compliance.
AXSM vs WK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $238.9M |
| Net Profit | $-28.6M | $11.8M |
| Gross Margin | — | 80.7% |
| Operating Margin | -13.8% | 3.3% |
| Net Margin | -14.6% | 4.9% |
| Revenue YoY | 65.0% | 19.5% |
| Net Profit YoY | 61.9% | 234.0% |
| EPS (diluted) | $-0.55 | $0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $238.9M | ||
| Q3 25 | $171.0M | $224.2M | ||
| Q2 25 | $150.0M | $215.2M | ||
| Q1 25 | $121.5M | $206.3M | ||
| Q4 24 | $118.8M | $199.9M | ||
| Q3 24 | $104.8M | $185.6M | ||
| Q2 24 | $87.2M | $177.5M | ||
| Q1 24 | $75.0M | $175.7M |
| Q4 25 | $-28.6M | $11.8M | ||
| Q3 25 | $-47.2M | $2.8M | ||
| Q2 25 | $-48.0M | $-19.4M | ||
| Q1 25 | $-59.4M | $-21.4M | ||
| Q4 24 | $-74.9M | $-8.8M | ||
| Q3 24 | $-64.6M | $-17.0M | ||
| Q2 24 | $-79.3M | $-17.5M | ||
| Q1 24 | $-68.4M | $-11.7M |
| Q4 25 | — | 80.7% | ||
| Q3 25 | — | 79.3% | ||
| Q2 25 | — | 77.0% | ||
| Q1 25 | — | 76.6% | ||
| Q4 24 | — | 77.1% | ||
| Q3 24 | — | 76.5% | ||
| Q2 24 | — | 76.8% | ||
| Q1 24 | — | 76.4% |
| Q4 25 | -13.8% | 3.3% | ||
| Q3 25 | -27.0% | -1.5% | ||
| Q2 25 | -24.5% | -10.3% | ||
| Q1 25 | -46.9% | -12.0% | ||
| Q4 24 | -61.1% | -6.7% | ||
| Q3 24 | -59.8% | -11.7% | ||
| Q2 24 | -89.5% | -13.0% | ||
| Q1 24 | -89.7% | -10.4% |
| Q4 25 | -14.6% | 4.9% | ||
| Q3 25 | -27.6% | 1.2% | ||
| Q2 25 | -32.0% | -9.0% | ||
| Q1 25 | -48.9% | -10.4% | ||
| Q4 24 | -63.1% | -4.4% | ||
| Q3 24 | -61.7% | -9.2% | ||
| Q2 24 | -91.0% | -9.9% | ||
| Q1 24 | -91.1% | -6.7% |
| Q4 25 | $-0.55 | $0.21 | ||
| Q3 25 | $-0.94 | $0.05 | ||
| Q2 25 | $-0.97 | $-0.35 | ||
| Q1 25 | $-1.22 | $-0.38 | ||
| Q4 24 | $-1.54 | $-0.15 | ||
| Q3 24 | $-1.34 | $-0.31 | ||
| Q2 24 | $-1.67 | $-0.32 | ||
| Q1 24 | $-1.44 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $338.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $-5.4M |
| Total Assets | $689.8M | $1.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $338.8M | ||
| Q3 25 | $325.3M | $315.9M | ||
| Q2 25 | $303.0M | $284.3M | ||
| Q1 25 | $300.9M | $242.0M | ||
| Q4 24 | $315.4M | $301.8M | ||
| Q3 24 | $327.3M | $248.2M | ||
| Q2 24 | $315.7M | $267.9M | ||
| Q1 24 | $331.4M | $296.1M |
| Q4 25 | $88.3M | $-5.4M | ||
| Q3 25 | $73.7M | $-36.9M | ||
| Q2 25 | $73.1M | $-66.5M | ||
| Q1 25 | $53.2M | $-75.7M | ||
| Q4 24 | $57.0M | $-41.7M | ||
| Q3 24 | $92.9M | $-50.8M | ||
| Q2 24 | $102.9M | $-77.7M | ||
| Q1 24 | $144.0M | $-83.2M |
| Q4 25 | $689.8M | $1.5B | ||
| Q3 25 | $669.3M | $1.4B | ||
| Q2 25 | $639.8M | $1.3B | ||
| Q1 25 | $596.7M | $1.3B | ||
| Q4 24 | $568.5M | $1.4B | ||
| Q3 24 | $561.5M | $1.3B | ||
| Q2 24 | $548.2M | $1.2B | ||
| Q1 24 | $545.7M | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $51.0M |
| Free Cash FlowOCF − Capex | $-18.7M | $50.7M |
| FCF MarginFCF / Revenue | -9.6% | 21.2% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 4.31× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $138.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $51.0M | ||
| Q3 25 | $1.0M | $46.2M | ||
| Q2 25 | $-32.4M | $50.3M | ||
| Q1 25 | $-43.4M | $-7.4M | ||
| Q4 24 | $-26.2M | $44.0M | ||
| Q3 24 | $-18.6M | $18.9M | ||
| Q2 24 | $-30.1M | $-14.0K | ||
| Q1 24 | $-53.5M | $24.8M |
| Q4 25 | $-18.7M | $50.7M | ||
| Q3 25 | $988.0K | $46.1M | ||
| Q2 25 | $-32.4M | $49.3M | ||
| Q1 25 | $-43.7M | $-8.1M | ||
| Q4 24 | $-26.2M | $43.2M | ||
| Q3 24 | $-18.7M | $18.7M | ||
| Q2 24 | $-30.2M | $-122.0K | ||
| Q1 24 | $-53.6M | $24.6M |
| Q4 25 | -9.6% | 21.2% | ||
| Q3 25 | 0.6% | 20.5% | ||
| Q2 25 | -21.6% | 22.9% | ||
| Q1 25 | -36.0% | -3.9% | ||
| Q4 24 | -22.1% | 21.6% | ||
| Q3 24 | -17.9% | 10.1% | ||
| Q2 24 | -34.6% | -0.1% | ||
| Q1 24 | -71.4% | 14.0% |
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.5% | ||
| Q1 25 | 0.3% | 0.4% | ||
| Q4 24 | 0.0% | 0.4% | ||
| Q3 24 | 0.1% | 0.1% | ||
| Q2 24 | 0.1% | 0.1% | ||
| Q1 24 | 0.1% | 0.1% |
| Q4 25 | — | 4.31× | ||
| Q3 25 | — | 16.57× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
WK
| License And Service | $219.3M | 92% |
| XBRL Professional Services | $16.4M | 7% |
| Other Services | $3.2M | 1% |
